Literature DB >> 25034569

Co-exposure to refractory ceramic fibres and asbestos and risk of pleural mesothelioma.

Aude Lacourt1, Mickael Rinaldo2, Céline Gramond2, Stéphane Ducamp3, Annabelle Gilg Soit Ilg4, Marcel Goldberg4, Jean Claude Pairon5, Patrick Brochard2.   

Abstract

The aim of this study was to investigate the hypothesis of an increased risk of pleural mesothelioma due to co-exposure to asbestos and refractory ceramic fibres (RCF) compared to asbestos exposure alone. Males were selected from a French case-control study conducted in 1987-1993 and from the French National Mesothelioma Surveillance Program in 1998-2006. Two population controls were frequency matched to each case by year of birth. Complete job histories were collected and occupational asbestos and RCF exposures were assessed using job exposure matrices. The dose-response relationships for asbestos exposure were estimated from an unconditional logistic regression model in subjects exposed to asbestos only (group 1) and subjects exposed to both asbestos and RCF (group 2). A total of 988 cases and 1125 controls ever-exposed to asbestos were included. A dose-response relationship was observed in both groups but it was stronger in group 2. In comparison with subjects exposed at the minimum value of the cumulative index of exposure, the odds ratio was 2.6 (95% CI 1.9-3.4) for subjects exposed to 75 fibres · mL(-1) · year(-1) in group 1 increasing to 12.4 (95% CI 4.6-33.7) in group 2. Our results suggest that the pleural carcinogenic effect of occupational asbestos exposure may be modified by additional exposure to RCF. ©ERS 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25034569     DOI: 10.1183/09031936.00079814

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  1 in total

1.  Mesothelioma in Sweden: Dose-Response Analysis for Exposure to 29 Potential Occupational Carcinogenic Agents.

Authors:  Nils Plato; Jan I Martinsen; Kristina Kjaerheim; Pentti Kyyronen; Pär Sparen; Elisabete Weiderpass
Journal:  Saf Health Work       Date:  2018-04-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.